CD80 expression promotes immune surveillance in Barrett's metaplasia

Melania Scarpa, Matteo Fassan, Andromachi Kotsafti, Stefano Realdon, Luigi Dall'Olmo, Tiziana Morbin, Francesco Cavallin, Luca Saadeh, Matteo Cagol, Rita Alfieri, Carlo Castoro, Massimo Rugge, Ignazio Castagliuolo, Marco Scarpa

Research output: Contribution to journalArticle

Abstract

Esophageal adenocarcinoma (EAC) is the final step of a pathway starting with esophageal reflux disease, Barrett's metaplasia and Barrett's dysplasia. Positive costimulatory ligands such as CD80 have been suggested to contribute to anti-tumor T-cell efficacy. Here we report for the first time the role of CD80 in the inflammatory esophageal carcinogenesis and characterize the immune environment of EAC. Mucosa samples from cancer were obtained during esophagectomy from patients affected by EAC. Fresh biopsies were obtained from patients who underwent endoscopy for screening or follow-up. A rodent model of reflux induced esophageal carcinogenesis was created with an esophago-gastro-jejunostomy. CD80 expression was increased in epithelial cells during metaplasia in the inflammatory esophageal carcinogenesis cascade. Cd80 null mice as well as WT mice that received antiCD80 antibodies showed a higher rate of dysplasia and KI-67+ cells. These results suggest that CD80 mediates an active immune surveillance process in early inflammation-driven esophageal carcinogenesis.

Original languageEnglish
Pages (from-to)e1636618
JournalOncoImmunology
Volume8
Issue number10
DOIs
Publication statusPublished - 2019

    Fingerprint

Cite this